Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: An open-label study

Journal of Rheumatology

Volumn 43, Issue 5, 2016, Pages 995-996

  Smith, Vanessa ^a   Pizzorni, Carmen ^b   Riccieri, Valeria ^c   Decuman, Saskia ^a   Brusselle, Guy ^d   De Pauw, Michel ^d   Deschepper, Ellen ^e   Piette, Yves ^d   Ruaro, Barbara ^b   Sulli, Alberto ^b   Vandecasteele, Els ^d   Melsens, Karin ^d   De Keyser, Filip ^a,d   Cutolo, Maurizio ^b  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF GENOA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB;

CAPILLAROSCOPY; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; LOW DRUG DOSE; MICROANGIOPATHY; MICROCIRCULATION; MODIFIED RODNAN SKIN SCORE; NAILFOLD VIDEOCAPILLAROSCOPY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; SKIN DISEASE; SKIN DISEASE ASSESSMENT; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

EID: 84966698081     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.151018     Document Type: Letter

References (10)

1. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437-44.
2. Denton CP, Ong VH. Targeted therapies for systemic sclerosis. Nat Rev Rheumatol 2013;9:451-64.
3. Moazedi-Fuerst FC, Kielhauser SM, Brickmann K, Hermann J, Lutfi A, Meilinger M, et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 2014;43:257-8.
4. Moazedi-Fuerst FC, Kielhauser SM, Bodo K, Graninger WB. Dosage of rituximab in systemic sclerosis: 2-year results of five cases. Clin Exp Dermatol 2015;40:211-2.
5. Fraticelli P, De Vita S, Franzolini N, Svegliati S, Scott CA, Tonnini C, et al. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Clin Exp Rheumatol 2015;33 Suppl 91:S160-7.
6. Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013;40:52-7.
7. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010;69:193-7.
8. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902-12.
9. Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885-7.
10. Smith V, Pizzorni C, De Keyser F, Decuman S, Van Praet JT, Deschepper E, et al. Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann Rheum Dis 2010;69:1092-6.